eFFECTOR Therapeutics Inc... (EFTR)
0.00
null (null%)
At close: Jan 14, 2025, 8:00 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 941 |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -12.57 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | n/a |
| Volume | 720 |
| Avg. Volume (20D) | 16,618 |
| Open | 0.00 |
| Previous Close | undefined |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 17.75 |
| Beta | undefined |
About EFTR
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit euk...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 1, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol EFTR
Website https://effector.com
Analyst Forecast
According to 1 analyst ratings, the average rating for EFTR stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 11999900.00% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
6 months ago ·
Source
-75.81%
EFFECTOR Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
9 months ago ·
Source
-82.03%
EFFECTOR Therapeutics shares are trading lower. The company announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer.
